Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

Glenmark Pharmaceuticals Ltd. on Wednesday announced that it has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa ...

Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company, has launched empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

The price of blockbuster diabetes drug empagliflozin has crashed as much as 90%, as several domestic drugmakers have announced the launch generic versions on Wednesday. Mankind Pharma, Alkem ...

Stock Market LIVE Updates | India's equity benchmark indices Sensex and Nifty were flat on Wednesday, as gains in Reliance Industries and Bharti Airtel, following their deals with Elon Musk's SpaceX ...

India’s diabetes drug market is amid an intense price war, with homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 ...

Glenmark Pharmaceuticals has introduced Glempa, a medication designed for glycemic control and weight-loss in type 2 diabetes patients. The drug, an SGLT2 inhibitor, aims to improve cardiovascular ...

NEW DELHI, Mar 12: Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched ...